Table 2 Modelled cost-benefit findings for TAVI compared with SAVR in the Netherlands
Summary results | TAVI | SAVR | Incremental |
|---|---|---|---|
Cost per patient | €44,149 | €39,407 | €4742 |
Life year gained (undiscounted) | 12.67 | 11.89 | 0.79 |
Median survival (years) | 15.00 | 13.17 | 1.83 |
QALYs per patient | 9.50 | 8.62 | 0.89 |
Incremental cost-effectiveness ratio (ICER) | €5346 | ||
Incremental net monetary benefit (NMB) | €39,615 | ||
Incremental net health benefit (NHB) | 0.79 | ||
Acute phase cost (initial procedure) | |||
Index hospitalization (without pacemaker)– including rehabilitation | €36,190 | €29,140 | €7050 |
Acute phase costs | €36,190 | €29,140 | €7050 |
Additional costs at 1 year | |||
MI | €123 | €84 | €38 |
Costs of pacemaker complications | €25 | €15 | €10 |
Costs of rehospitalizations | €177 | €265 | –€88 |
Re-intervention costs | €163 | €161 | €1 |
Alive and well health state costs | €270 | €181 | €89 |
Treated AF health state costs | €45 | €350 | –€305 |
DS costs | €46 | €181 | –€135 |
Death costs | €0 | €0 | €0 |
Total costs at 1 year | €36,190 | €29,140 | €7,050 |
Additional lifetime costs | |||
Costs of pacemaker complications | €241 | €140 | €101 |
Costs of rehospitalizations | €266 | €252 | €15 |
Re-intervention costs | €4,171 | €3,642 | €529 |
Alive and well health state costs | €750 | €474 | €276 |
Treated AF health state costs | €722 | €3075 | –€2353 |
DS costs | €1808 | €2684 | –€876 |
Death costs | €0 | €0 | €0 |
Additional lifetime costs | €7959 | €10,267 | –€2308 |
Total lifetime costs | €44,149 | €39,407 | €4742 |